NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - East of England, London and South East Coast

This tender has closed.

See what's open in health and social care services, or get contracts like this in your inbox each morning — free.

About this contract

NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - East of England, London and South East Coast. Offer reference number: CM/PHS/19/5580 Period of framework agreement: 1 July 2020 - 30 June 2021 with options to extend up to a further 36 months. Total maximum framework agreement including extension options will be no more than 48 months Additional information: Document No.05a - Offer Schedule, published on Bravo, has been amended and an updated version, Document No.05a - Offer Schedule (Reissue), has been published on Bravo today. The revised document reflects changes made to the listed Bevacizumab products which were incorrectly listed as pre-filled syringes instead of infusion bags. Please ensure you used the updated document when submitting your offer. Document No.05a - Offer Schedule (Reissue) published on Bravo, has been amended and an updated version, Document No.05a - Offer Schedule (Reissue v2) has been published on Bravo today. The revised document reflects changes made to the "low volume product" list which incorrectly included Pertuzumab. In addition, the estimated total annual usage in single units (NoE) was blanked out for products that are not being awarded to that region under this tender. The cells have been cleared of data in the updated version. Please ensure you use the updated document when submitting your offer. Document No.05c - Award Methodology and Criteria, published on Bravo, has been amended and an updated version, Document No.05c - Award Methodology and Criteria (Reissue) has been published on Bravo today. The revised document reflects changes made to the "low volume product" list which incorrectly included Pertuzumab. Please ensure you use the updated document when submitting your offer. Document No.04e - Standard Product Specifications published on Bravo, has been amended and an updated version, Document No.04e - Standard Product Specification (Reissue) has been published on Bravo today. The revised document reflects a change made to the Bortezomib specification which now states "Licensed Bortezomib injection". In addition, the revised document reflects a change made to the Ganciclovir specification which now states volume of "50ml or 100ml". Please ensure you used the updated document when submitting your offer. Document No.03 - Framework Agreement and Terms and Conditions, published on Bravo, has been amended and an updated version, Document No.03 - Framework Agreement and Terms and Conditions (Reissue), has been published on Bravo today. The revised document reflects a change made to the Ordering Procedure (Schedule 7) paragraph 1.2.2 which now states "send an Order to the Framework Provider as set out in clause 3 of this Schedule 7 following the evaluation of its Offer". Please ensure you refer to the updated document when submitting your offer. Document No.05a - Offer Schedule (Reissue v2), published on Bravo, has been amended and an updated version, Document No.05a - Offer Schedule (Reissue v3), has been published on Bravo today, 3 March 2020. The revised document reflects changes made under 'Tab 2 Pricing Schedule'. These changes indicate that under the heading Product Description, the eleven rows indicating Nivolumab 120mg to 480mg (inclusive) should read /100ml - not /50ml as previously advised.

Key dates

Source

Who to contact

Tender documents

Similar open tenders